Medical device coating technology company Hydromer, Inc. reported preliminary unaudited financial results for 2024, revealing a 12% decline in total revenue to $3.59 million. The decrease stems from legacy program attrition and insufficient research and development investments, which limited the company's ability to introduce new products and maintain its customer base.
CEO Michael Torti acknowledged the revenue challenges, emphasizing that current management is actively restructuring the business to enhance future performance. Key strategic initiatives include investing in product development, strengthening customer relationships, and exploring new market opportunities.
Despite the revenue decline, the company reported a normalized net loss of $83,000 on a cash-adjusted basis. Hydromer is particularly focused on advancing a next-generation UV-curable coating formulation, which could potentially create new revenue streams and address emerging market demands.
The company's strategic pivot centers on operational efficiency and long-term growth. By developing innovative solutions that align with industry needs, Hydromer aims to replenish its product pipeline and reestablish its competitive position in the medical device coating technology sector.
